As a result of this study, the nanoliposome encapsulated HSP70.PC derived from DC-tumor fusion cells (NL-HSP.PC70-Fc) has been found to improve the immunogenicity as compared to HSP.PC70-Tu derived from tumors, and increase the bioavailability compared to HSP.PC70-Fc. This evidence concerns the gene HSP90B2P and neoplasm.